While the results represent small patient numbers, Telix Pharmaceuticals has encouraging early Phase II data for TLX101 (131 I-iodofalan) in patients with recurrent high-grade gliomas, including glioblastoma (GBM), which likely warrants further study.
Key Takeaways
- Telix announced Phase II data for a handful of patients, showing an overall survival increase among patients with high-grade gliomas, including glioblastoma.
- The data showed a nearly three-month overall survival improvement compared with historical OS rates for patients receiving radiation alone in a disease that typically is rapidly fatal
The Melbourne, Australia-based firm on 15 April announced results from eight patients in the single-arm, investigator-initiated IPAX-Linz trial of external beam radiation therapy combined with TLX101, a systemically administrated radiation therapy that targets L-type amino acid transporter 1 (LAT1)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
